{
    "root": "1ea9dc72-fe7e-4c38-b901-0efffb674f28",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Contrave",
        "suffix": {
            "text": "Extended-Release"
        }
    },
    "value": "20250507",
    "ingredients": [
        {
            "name": "NALTREXONE HYDROCHLORIDE",
            "code": "Z6375YW9SF"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "CYSTEINE HYDROCHLORIDE",
            "code": "ZT934N0X4W"
        },
        {
            "name": "CROSPOVIDONE (120 .MU.M)",
            "code": "68401960MK"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        }
    ],
    "indications": "CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:\n                  \n                     30 kg/m2 or greater (obese) or\n                     27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).",
    "contraindications": "CONTRAVE dose escalation schedule ( 2.1 ): Morning Dose Evening Dose Week 1 1 tablet None Week 2 1 tablet 1 tablet Week 3 2 tablets 1 tablet Week 4 â€“ Onward 2 tablets 2 tablets",
    "warningsAndPrecautions": "CONTRAVE 8 mg/90 mg (naltrexone HCl 8 mg and bupropion HCl 90 mg) extended-release tablets are blue, round, bi-convex, film-coated tablets debossed with \"NB-890\" on one side. CONTRAVE tablets are available as follows:\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                           NDC 51267-890-99\n                           Bottles of 120 tablets",
    "adverseReactions": "CONTRAVE is contraindicated in\n                  \n                     Uncontrolled hypertension [see Warnings and Precautions (5.5)]\n                     \n                     Seizure disorder or a history of seizures [see Warnings and Precautions (5.3)]\n                     \n                     Use of other bupropion-containing products (including, but not limited to, WELLBUTRIN, WELLBUTRIN SR, WELLBUTRIN XL, APLENZIN and ZYBAN)\n                     Bulimia or anorexia nervosa, which increase the risk for seizure [see Warnings and Precautions (5.3)]\n                     \n                     Chronic opioid or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal [see Warnings and Precautions (5.4) and Drug Interactions (7.2)]\n                     \n                     Patients undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [see Warnings and Precautions (5.3) and Drug Interactions (7.7)]\n                     \n                     Concomitant administration of monoamine oxidase inhibitors (MAOI). At least 14 days should elapse between discontinuation of MAOI and initiation of treatment with CONTRAVE. There is an increased risk of hypertensive reactions when CONTRAVE is used concomitantly with MAOIs. Starting CONTRAVE in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated [see Dosage and Administration (2.4), Drug Interactions (7.1)]\n                     \n                     Known allergy to bupropion, naltrexone or any other component of CONTRAVE. Anaphylactoid/anaphylactic reactions and Stevens-Johnson syndrome have been reported with bupropion [see Warnings and Precautions (5.6)]"
}